According to the results of a recently published nested case-control study, exposure to any benzodiazepine in early pregnancy may increase the risk of spontaneous abortion (SA).
Generalized fractional anisotropy reductions in bundles connecting regions involved in mood regulation and motor function were seen in patients with schizophrenia and bipolar disorder.
The Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to SEP-363856 (Sunovion), an investigational treatment for schizophrenia.
Patients with schizophrenia who participated in a telephone intervention problem-solving program were found to have higher rates of medication adherence compared with patients who received routine hospital care for schizophrenia.
Researchers found data to support the benefits of proactively helping patients with schizophrenia quit smoking, including the idea to try to create a substitute that would give patients the benefits that they find by self-medicating with cigarettes, but without the unhealthy adverse effects.
Prevention programs may improve long-term outcomes in children and adolescents by addressing pre-existing vulnerabilities that increase the risk for exposure to bullying.
Patients with bipolar disorder may be at increased risk for suicide attempts if they live in a location with large changes in solar insolation between winter and summer.
According to the results of a retrospective observational study, the majority of pharmacotherapies used for the treatment of bipolar disorder (BD) are associated with some risk of kidney disorder (KD).
When combined with other serotonergic agents, selective serotonin reuptake inhibitors can lead to a potentially fatal condition called serotonin syndrome, the incidence of which is likely underestimated.
